Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 3/20 | 0.51 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30476346 | 1.00 | TRPC5 (0.51) | TRPC5SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL20818111 | 0.84 | TRPC5 (0.56) | TRPC5SMARCA2SMARCA4PBRM1 | |
| SCHEMBL20818370 | 0.84 | TRPC5 (0.56) | TRPC5SMARCA2SMARCA4PBRM1 | |
| SCHEMBL20817915 | 0.83 | TRPC5 (0.50) | TRPC5SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL20831929 | 0.79 | TRPC5 (0.46) | TRPC5GPR119IDO1TDO2SETD7 | |
| SCHEMBL20818796 | 0.78 | PSEN1 (0.43) | TRPC5GPR119IDO1TDO2SPR | |
| SCHEMBL30867811 | 0.78 | GPR119 (0.52) | SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL16605 | 0.75 | GPR119 (0.61) | SMARCA2SMARCA4PBRM1GPR119SETD7 | |
| SCHEMBL1447946 | 0.75 | GPR119 (0.61) | SMARCA2SMARCA4PBRM1GPR119SETD7 | |
| SCHEMBL1447948 | 0.75 | GPR119 (0.61) | SMARCA2SMARCA4PBRM1GPR119SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | TRPC5 1439/4885SMARCA2 3392/4885SMARCA4 3400/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | TRPC5 1439/4885SMARCA2 3392/4885SMARCA4 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.